Potential new target for drugs to prevent HIV-associated dementia
New Australian research has shown that Indigenous Australians with kidney disease are confused, frustrated and feel poorly informed about their illness. The study reveals Indigenous Australian’s feel inadequately informed and are considerably more uncertain about the cause of their illness compared to non-Indigenous patients with kidney disease. The results of the large qualitative study are
Full Post: Indigenous Australian’s inadequately informed about kidney disease
A new study led by researchers at Albert Einstein College of Medicine of Yeshiva University has clarified how two major variants of HIV differ in their ability to cause neurologic complications.
The finding, published in Journal of Neuroscience, highlights a new target for drugs that could prevent HIV-associated dementia, an incurable and increasingly common complication in people with AIDS. Even with anti-retroviral drug therapies, up to one-half of people infected with HIV will develop mild to moderate neurological complications, according to some estimates.
Earlier this decade, scientists observed that people with AIDS in India developed dementia at a far lower rate than comparable populations in the U.S. and Western Europe. Most cases of AIDS in India are due to infection with a subtype or clade of HIV, known as clade C, while most cases in the U.S. and Western Europe are due to clade B.
Based on these observations, in 2004, a team of researchers led by Dr. Vinayaka R. Prasad, professor of microbiology and immunology at Einstein, began searching for genetic variations between the two clades that could explain the differing rates of HIV-related dementia. The team, in collaboration with Dr. Udaykumar Ranga of the Jawaharlal Nehru Centre for Advanced Scientific Research in Bangalore, India, focused their search on Tat, a protein that helps HIV replicate and leads the attack on the brain.
Dr. Prasad and colleagues compared the sequences of the Tat protein of the two clades and noted a key difference. Where the clade B Tat protein contained the amino acid cysteine at a specific position in the Tat protein, the clade C Tat had the amino acid serine. The next step, and the focus of the current study, was to compare the two viruses in a single host to determine whether this key change in the amino acid sequence makes a practical difference in HIV’s neurotoxicity.
To find out, the researchers injected either clade B or clade C HIV into the brain of a special strain of immunodeficient mice. After six days–enough time for the viruses to cause neurologic damage–the mice were tested in a complex water maze that challenged their long term memory as well as their short term working memory (the type that temporarily stores and manages the information needed to carry out complex cognitive tasks, such as learning, reasoning, and comprehension).
Mice infected with clade B performed significantly worse in the maze than those infected with clade C. Moreover, when the researchers examined the mouse brains, they found more damage to neurons in the brains of mice injected with clade B than with clade C. These results were in line with the fact that people infected with clade B HIV are at greater risk for dementia than people infected with clade C.
This is the first evidence in an animal model that HIV variants from different parts of the world differ in their ability to cause neurological complications. Further, test tube studies conducted at Einstein showed strain differences in recruiting inflammatory cells to the brain. Thus, these data now provide biological evidence that Tat protein plays a crucial role in the development of HIV-related dementia.
“Tat seems to be responsible for most of the neurological symptoms seen in patients with HIV-associated dementia,” says Dr. Prasad. “People have always suspected Tat to be a key protein in HIV dementia based on test tube studies. Credit for that work belongs to, among others, Dr. Joan Berman, also from Einstein. Our results, obtained using live virus in an animal model to compare genetic variants, suggest that a drug that targets HIV-1 Tat might prevent the neurological effects of AIDS.”
The need for drugs that prevent HIV-dementia has grown more acute in recent years, notes Dr. Prasad. Thanks to advances in therapy, people with HIV are living increasingly longer. In 1996, a 20-year-old newly diagnosed with HIV could expect to live another 36 years, according to a recent study in The Lancet. Today, that same person could expect to live another 49 years. However, because anti-retroviral drugs do not fully eradicate HIV from the brain or the rest of the body, the low levels of virus that remain can cause significant damage.
The findings raise a larger issue, say the researchers. There appear to be significant differences between the major strains of HIV, perhaps warranting different therapeutic approaches. “Roughly 60 percent of the HIV infections worldwide are due to clade C, but all effective therapies are based on clade B,” says Dr. Vasudev R. Rao, lead author of the study and research associate in microbiology and immunology at Einstein. “While our findings specifically address the differences between clade B and clade C with regard to the manifestation of HIV-associated dementia, investigating subtype differences has broad implications for clinical management and treatment for the global AIDS epidemic.”
Scientists at Albert Einstein College of Medicine of Yeshiva University have identified a small intracellular protein that helps cells commit suicide. The finding, reported as the “paper of the week” in the January 16th print issue of the Journal of Biological Chemistry, could lead to drugs for combating cancer and other diseases characterized by overproduction
Full Post: Discovery of protein that amplifies cell death
Patients with dementia and diabetes appear to display a different pattern of injuries in their brains than patients with dementia but without diabetes, according to an article posted online today that will appear in the March print issue of Archives of Neurology. “The association between diabetes mellitus and increased risk for dementia in the elderly
Full Post: Diabetes associated with different types of brain injury in patients with dementia
Researchers at the Indiana University School of Medicine have identified a potential new target in the war on HIV/AIDS. The information was published in the Jan. 16 issue of the journal Molecular Cell . The study revealed that a variant of a protein involved in HIV pathogenesis can suppress production of an HIV protein, known
Full Post: Potential new target in the war on HIV/AIDS
Swedish research has found a link between fast food and Alzheimer’s disease. The research by scientists at the Karolinska Institutet has revealed that mice fed a diet of junk food for a nine month period developed the abnormal brain tangles which are seen in the preliminary stages of Alzheimer’s disease - they say a
Full Post: Fast food diet a suspect in Alzheimer’s disease
Scientists have unraveled in unprecedented detail the cascade of events that go wrong in brain cells affected by HIV, a virus whose assault on the nervous system continues unabated despite antiviral medications that can keep the virus at bay for years in the rest of the body. The new research reveals key steps taken in
Full Post: New research reveals key steps in HIV’s assault on the brain